在华法林治疗中应用华法林个性化药物遗传变异的快速基因定型
Defa Huang1, Fangfang Xie1, Shengpeng Xiao2
1Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China.
Scientific reports
|December 31, 2024
概括
使用全血的新型,快速和低成本的多重检测直接识别影响华法林剂量的遗传变异. 这种方法通过精确的基因定型关键单核酸多态 (SNP) 来增强个性化抗凝剂治疗.
科学领域:
- 药物基因组学 药物基因组学
- 分子诊断学 分子诊断
背景情况:
- 华法林是一种广泛使用的口服抗凝剂,但其剂量受遗传变异的影响.
- 准确的细胞染色体P450 2C9 (CYP2C9),维生素K环氧减少酶复合体1 (VKORC1) 和细胞染色体P450 4F2 (CYP4F2) 的基因定型对于个性化的华法林治疗至关重要.
- 目前的基因造型方法耗时,昂贵,容易受到污染,限制了临床效用.
研究的目的:
- 开发和验证一种新的,快速的,经济高效的多重测定方法,用于基因定型影响华法林剂量要求的单核酸多态 (SNP).
- 评估全血直接放大嵌套聚合酶链反应 (PCR) 多重光化曲线试验的临床适用性.用于药物遗传学测试.
主要方法:
- 使用全血直接放大和嵌套PCR的多重光化曲线试验被开发用于同时对CYP2C9,VKORC1和CYP4F2SNP进行基因定型.
- 测试只需要1μL的全血,不需要DNA提取,在不到2小时内完成,成本不到1美元.
- 从181名华法林治疗患者的基因定型结果与通过标准基因测序获得的结果进行了比较.
主要成果:
- 新的多重测试表明与基因测序100%一致,表明高精度和特异性.
- 该试验成功地基因型化了四个关键的多态位点:CYP2C9*3 (rs1057910),VKORC1 (rs99231),CYP4F2*3 (rs2108622) 和CYP2C9*2 (rs1799853).
- 在特定基因型和华法林剂量要求之间观察到显著的关联,包括CYP2C9*1*1和VKORC1 (AA) 基因型的较低剂量,以及CYP4F2*3突变的个体的较高剂量.
结论:
- 通过嵌套PCR进行全血直接放大的多重光化曲线测定提供了一个高度准确,快速和具有成本效益的方法来对影响华法林疗效的SNP进行基因定型.
- 这种创新方法非常适合临床应用,促进基于遗传信息的个性化华法林抗凝药疗法.
更多相关视频
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.1K
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
Published on: August 21, 2016
12.9K
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:11Genome-wide Association Studies-GWAS
12.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.4K
01:12Analysis of Population Pharmacokinetic Data
224
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
224
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
608
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
608